Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Xencor Inc (XNCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/06/2025: XNCR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -20.35% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/06/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 682.78M USD | Price to earnings Ratio - | 1Y Target Price 30.3 |
Price to earnings Ratio - | 1Y Target Price 30.3 | ||
Volume (30-day avg) 532660 | Beta 0.74 | 52 Weeks Range 9.65 - 27.24 | Updated Date 04/1/2025 |
52 Weeks Range 9.65 - 27.24 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -210.53% | Operating Margin (TTM) 9.11% |
Management Effectiveness
Return on Assets (TTM) -11.48% | Return on Equity (TTM) -35.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 413369152 | Price to Sales(TTM) 7.16 |
Enterprise Value 413369152 | Price to Sales(TTM) 7.16 | ||
Enterprise Value to Revenue 4.76 | Enterprise Value to EBITDA -17.27 | Shares Outstanding 70461904 | Shares Floating 63604579 |
Shares Outstanding 70461904 | Shares Floating 63604579 | ||
Percent Insiders 1.13 | Percent Institutions 107.68 |
Analyst Ratings
Rating 4.42 | Target Price 32.91 | Buy 4 | Strong Buy 7 |
Buy 4 | Strong Buy 7 | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Xencor Inc
Company Overview
History and Background
Xencor, Inc. was founded in 1997. It focuses on engineering antibodies and cytokines to create medicines for cancer and autoimmune diseases. It has evolved from a research-focused company to one with partnered and proprietary clinical programs.
Core Business Areas
- XmAb Antibody Engineering: Xencor's core technology platform is XmAb, which involves modifying the Fc region of antibodies to enhance or reduce their effector functions.
- Clinical Development: Xencor develops its own pipeline of antibody-based therapeutics targeting various diseases, including cancer and autoimmune disorders.
- Partnered Programs: Xencor collaborates with pharmaceutical companies to develop and commercialize XmAb-engineered antibodies.
Leadership and Structure
Xencor is led by a management team with expertise in antibody engineering and drug development. The organizational structure is typical of a biotechnology company, with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- Monjuvi (tafasitamab-cxix): Monjuvi is an anti-CD19 antibody approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It's co-marketed with Incyte. Revenue information is publicly available in financial reports. Competitors: Rituxan, Polivy.
- Vijoice (vilobelimab): Vijoice is an anti-APRI antibody approved for treatment of adults with severe COVID-19. Revenue information is publicly available in financial reports. Competitors: Remdesivir.
- XmAb Platform Technology: The XmAb platform is licensed to various pharmaceutical companies for their own drug development programs, generating revenue through licensing fees and royalties. Competitors: None directly, but alternative antibody engineering platforms exist.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, high R&D costs, and regulatory hurdles. There's a growing demand for novel antibody-based therapeutics, especially in oncology and autoimmune diseases.
Positioning
Xencor is positioned as an innovative antibody engineering company with a validated technology platform and a growing pipeline of proprietary and partnered programs. Its competitive advantage lies in its XmAb platform's ability to fine-tune antibody effector functions.
Total Addressable Market (TAM)
The total addressable market for antibody therapeutics is estimated to be in the hundreds of billions of dollars. Xencor is positioned to capture a share of this market through its partnered and proprietary programs.
Upturn SWOT Analysis
Strengths
- Validated XmAb platform technology
- Strong intellectual property portfolio
- Experienced management team
- Partnerships with major pharmaceutical companies
- Growing pipeline of clinical programs
Weaknesses
- Reliance on partnered programs for revenue
- High R&D costs
- Dependence on regulatory approvals
- Competition from larger pharmaceutical companies
Opportunities
- Expansion of the XmAb platform to new therapeutic areas
- Development of novel antibody-based therapeutics
- Strategic acquisitions and partnerships
- Geographic expansion
- Increased adoption of antibody therapeutics
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from biosimilars
- Patent challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- AMGN
- REGN
- GSK
- JNJ
Competitive Landscape
Xencor's advantage lies in its XmAb platform. Disadvantages include smaller size and fewer resources compared to larger pharmaceutical companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Xencor's historical growth has been driven by its partnered programs and the clinical progress of its proprietary pipeline.
Future Projections: Analyst projections vary, but generally expect continued growth driven by pipeline advancements and potential new partnerships.
Recent Initiatives: Recent initiatives include expanding its pipeline of clinical programs, securing new partnerships, and advancing its XmAb platform.
Summary
Xencor is a biotechnology company with a strong antibody engineering platform and a growing pipeline. While it relies on partnered programs, its proprietary assets offer future growth potential. Clinical trial outcomes and competition remain key risks.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
BIIB
Biogen Inc
BIIB
Biogen Inc
MRNA
Moderna Inc
MRNA
Moderna Inc
REGN
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is an estimation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xencor Inc
Exchange NASDAQ | Headquaters Pasadena, CA, United States | ||
IPO Launch date 2013-12-03 | Co-Founder, CEO, President & Director Dr. Bassil I. Dahiyat Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 250 | Website https://www.xencor.com |
Full time employees 250 | Website https://www.xencor.com | ||
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.